NCT00079716 - Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

November 30, 2007

Conditions

Multiple Myeloma

Interventions

DRUG

SGN-40 (anti-huCD40 mAb)

0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.

Trial Locations (5)

Cornell University, New York

The Cleveland Clinic, Cleveland

Rocky Mountain Cancer Center, Denver

James R. Berenson M.D., Inc., West Hollywood

Dana Farber Cancer Institute, Boston